|View printer-friendly version|
|August 13, 2000 3:29 p.m.|
|Teva Received Marketing Approval for Copaxone® in the U.K.|
The U.K. has agreed to act as a reference member state for the E.U wide registration
JERUSALEM, Israel, August 13, 2000 - Teva Pharmaceutical Industries, Ltd., (Nasdaq: TEVA) announced today that Copaxone® was approved for marketing in the U.K. This is the first approval in a major European market and enables Teva to file for approval all over the E.U. under the mutual recognition procedure.